Skip to content
HowShorted

Ernexa Therapeutics Inc. short interest in 2019

In 2019, Ernexa Therapeutics Inc.'s disclosed short interest ran from 1.21% of shares outstanding on 15 Jan 2019 to 0.03% on 31 Dec 2019, a change of -1.18 percentage points. The year's high was 1.46% on 31 Jan 2019 and its low 0.02% on 15 Aug 2019, averaging 0.61% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.47 days on 15 Apr 2019. Full history: Ernexa Therapeutics Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Ernexa Therapeutics Inc. in 2019

2019 in figures

Start of year
1.21% (15 Jan 2019)
End of year
0.03% (31 Dec 2019)
Change
-1.18 pp
High
1.46% (31 Jan 2019)
Low
0.02% (15 Aug 2019)
Average
0.61%
Highest days to cover
8.47 (15 Apr 2019)
SEC filings marked
8

Every report in 2019

Ernexa Therapeutics Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20191.21%1.00
31 Jan 20191.46%1.38
15 Feb 20191.37%4.59
28 Feb 20191.37%5.88
15 Mar 20191.35%7.83
29 Mar 20191.16%3.59results (8-K), 10-K filed
15 Apr 20191.13%8.47
30 Apr 20191.00%4.33
15 May 20190.89%4.32results (8-K), 10-Q filed
31 May 20190.98%6.42
14 Jun 20190.81%4.45
28 Jun 20190.63%3.64
15 Jul 20190.33%1.78
15 Aug 20190.02%1.00results (8-K), 10-Q filed
30 Aug 20190.04%1.00
13 Sep 20190.03%1.00
30 Sep 20190.03%1.00
15 Oct 20190.03%1.00
31 Oct 20190.05%1.00results (8-K)
15 Nov 20190.03%1.0010-Q filed
29 Nov 20190.02%1.00
13 Dec 20190.02%1.00
31 Dec 20190.03%1.00

See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.